DH / Definitive Healthcare Corp. - Документы SEC, Годовой отчет, Доверенное заявление

Компания Definitive Healthcare Corp.
US ˙ NasdaqGS ˙ US24477E1038

Основная статистика
CIK 1861795
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Definitive Healthcare Corp.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
August 7, 2025 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Definitive

August 7, 2025 EX-99.1

Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2025 Second Quarter Revenue Exceeded Guidance

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2025 Second Quarter Revenue Exceeded Guidance Framingham, MA (August 7, 2025) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended June 30, 2025. Second Quarter

August 7, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Definitive Healthc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 001-40815 Delaware 86-3988281 (State of Incorporation) (IRS Em

July 23, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2025 Definitive Healthca

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2025 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 001-40815 Delaware 86-3988281 (State of Incorporation) (IRS Emp

July 1, 2025 8-K

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 001-40815 Delaware 86-3988281 (State of Incorporation) (IRS Emp

June 6, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Definitive Healthcar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Commission File Number 001-40815 Delaware 86-3988281 (State of Incorporation) (IRS Empl

May 8, 2025 EX-10.3

Form of Executive Performance-Based Restricted Stock Unit Award Agreement under Definitive Healthcare Corp. 2021 Equity Incentive Plan (2025).

Exhibit 10.3 Definitive Healthcare Corp. 2021 Equity Incentive Plan Restricted Stock Unit Award Agreement (Performance-Based) This Restricted Stock Unit Award Agreement (this “Agreement”) is made by and between Definitive Healthcare Corp., a Delaware corporation (the “Company”), and [●] (the “Participant”), effective as of [●] (the “Date of Grant”). RECITALS WHEREAS, the Company has adopted the De

May 8, 2025 EX-99.1

Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025 First Quarter Revenue Exceeded Guidance

Exhibit 99.1 Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025 First Quarter Revenue Exceeded Guidance Framingham, MA (May 8, 2025) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025

May 8, 2025 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Definitive Healthcare

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 001-40815 Delaware 86-3988281 (State of Incorporation) (IRS Emplo

May 8, 2025 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Definitive

April 23, 2025 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

April 23, 2025 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

February 27, 2025 EX-99.1

Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024 Fourth quarter and full year 2024 revenue exceeded guidance

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024 Fourth quarter and full year 2024 revenue exceeded guidance Framingham, MA (February 27, 2025) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and

February 27, 2025 EX-FILING FEES

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Definitive Healthcare Corp.

February 27, 2025 EX-10.38

Employment Agreement, dated as of July 17, 2023, by and between Definitive Healthcare, LLC and William Moschella.

Exhibit 10.38 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is by and between Definitive Healthcare, LLC (the “Company”), and William Moschella (“Employee” or “You”) (collectively referred to as the “Parties” or individually referred to as a “Party”). The “Effective Date” of this Agreement will be the Closing Date as defined in that certain Agreement and Plan of Merger dated as

February 27, 2025 EX-21.1

List of subsidiaries.

Exhibit 21.1 Subsidiaries of the Registrant Entity Name Jurisdiction of Incorporation AIDH TopCo, LLC Delaware AIDH Buyer, LLC Delaware Definitive Healthcare Holdings, LLC Delaware Definitive Healthcare, LLC Massachusetts Analytical Wizards, Inc Delaware Analytical Wizards Services Private Ltd India Monocl Holding Company, LLC Delaware Monocl Company, LLC Delaware Monocl AB Sweden Healthcare Sales

February 27, 2025 EX-19.1

Definitive Healthcare Corp. Insider Trading Policy.

Exhibit 19.1 Insider Trading Policy I. INTRODUCTION A. Purpose The purpose of this Insider Trading Policy (this “Policy”) is to help Definitive Healthcare Corp. and its subsidiaries (the “Company”) comply with U.S. federal and state securities laws relating to insider trading, as well as similar laws in other countries where the Company does business, and to preserve the reputation and integrity o

February 27, 2025 EX-10.39

Holdback Agreement, dated as of July 17, 2023, by and between Analytical Wizards, Inc. and Masheen, LLC.

Exhibit 10.39 HOLDBACK AGREEMENT This Holdback Agreement (this “Agreement”), dated as of July 17, 2023 is entered into by and between Analytical Wizards, Inc., a Delaware corporation (“Parent”), and (ii) Masheen, LLC (the “Holdback Stockholder” and, together with Parent, the “Parties” and each, individually, a “Party”). RECITALS WHEREAS, concurrently with the execution and delivery of this Agreeme

February 27, 2025 EX-10.29

The Amended and Restated Definitive Healthcare Corp. 2023 Inducement Plan.

Exhibit 10.29 DEFINITIVE HEALTHCARE CORP. AMENDED AND RESTATED 2023 INDUCEMENT PLAN 1. General. 1.1 Purpose. The purpose of the Definitive Healthcare Corp. 2023 Inducement Plan is to further align the interests of eligible participants with those of the Company’s stockholders by providing incentive compensation opportunities tied to the performance of the Company and its Common Stock. The Plan is

February 27, 2025 EX-10.1

Offer Letter, dated February 24, 2025, by and among Casey Heller, Definitive Healthcare Corp. and Definitive Healthcare, LLC.

Exhibit 10.1 February 24, 2025 Casey Heller [**************************] [****************] [*******************] Dear Casey: We are thrilled to present you with the following letter outlining an offer to of promotion to the role of Chief Financial Officer of Definitive Healthcare, LLC, a Massachusetts limited liability company (the “Company”) and its parent company, Definitive Healthcare Corp., a

February 27, 2025 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 001-40815 Delaware 86-3988281 (State of Incorporation) (IRS

February 27, 2025 10-K

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40815 Definitive Heal

February 27, 2025 S-8

As filed with the Securities and Exchange Commission on February 27, 2025

As filed with the Securities and Exchange Commission on February 27, 2025 Registration No.

January 16, 2025 EX-10.1

Amendment No. 2, dated as of January 16, 2025, to Credit Agreement, dated September 17, 2021, by and among Definitive Healthcare Holdings, LLC, AIDH Buyer, LLC, the other loan guarantors from time to time party thereto, Bank of America, N.A., as Administrative Agent, the lenders party thereto and the issuing banks from time to time party thereto.

Exhibit 10.1 AMENDMENT NO. 2 THIS AMENDMENT NO. 2 (this “Amendment”), dated as of January 16, 2025, is entered into among Definitive Healthcare Holdings, LLC, a Delaware limited liability company (the “Borrower”), AIDH Buyer, LLC, a Delaware limited liability company (“Holdings”), the other Loan Guarantors party hereto, the Lenders party thereto and Bank of America, N.A., as administrative agent a

January 16, 2025 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 001-40815 Delaware 86-3988281 (State of Incorporation) (IRS

November 12, 2024 SC 13G

DH / Definitive Healthcare Corp. / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DEFINITIVE HEALTHCARE CORP. (Name of Issuer) Common Stock (Title of Class of Securities) 24477E103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b

November 7, 2024 EX-99.1

Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2024 Third quarter revenue exceeded guidance, and the Company announced a $100 million repurchase authorization

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2024 Third quarter revenue exceeded guidance, and the Company announced a $100 million repurchase authorization Framingham, MA (November 7, 2024) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced fi

November 7, 2024 EX-10.1

Voting Agreement, dated November 7, 2024 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40815) filed with the SEC on November 7, 2024).

Exhibit 10.1 VOTING AGREEMENT This Voting Agreement, dated as of November 7, 2024 (this “Agreement”), is entered into by and among Definitive Healthcare Corp., a Delaware corporation (the “Company”), Advent International, L.P., a Delaware limited partnership (“Advent”), and each of the other undersigned parties hereto (together with Advent, the “Advent Stockholders”). Each of the Company and the A

November 7, 2024 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 001-40815 Delaware 86-3988281 (State of Incorporation) (IRS

November 7, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Defini

October 3, 2024 EX-1

1. Joint Filing Agreement, dated as of October 3, 2024, by and between Irenic Capital Management LP, Irenic Capital Evergreen Master Fund LP, Adam Katz and Andrew Dodge.

EX-1 2 ex1.htm Exhibit 1 JOINT FILING AGREEMENT This Agreement will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on the date hereof with respect to the beneficial ownership by the undersigned of the shares of Class A Common Stock of Definitive Healthcare Corp. is being filed, and all amendments thereto will be filed, on

October 3, 2024 SC 13G

DH / Definitive Healthcare Corp. / Irenic Capital Management LP Passive Investment

SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Definitive Healthcare Corp. (Name of Issuer) Class A Common Stock, $0.001 par value (Title of Class of Securities) 24477E103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropr

October 1, 2024 8-K

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2024 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 001-40815 Delaware 86-3988281 (State of Incorporation) (IR

August 5, 2024 EX-99.1

Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2024 Second quarter revenue grew 5% year-over-year to $63.7 million

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2024 Second quarter revenue grew 5% year-over-year to $63.7 million Framingham, MA (August 5, 2024) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended June 30

August 5, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Definitive

August 5, 2024 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 001-40815 Delaware 86-3988281 (State of Incorporation) (IRS Em

July 30, 2024 8-K

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 001-40815 Delaware 86-3988281 (State of Incorporation) (IRS Emp

July 8, 2024 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 4, 2024 Definitive Healthcar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 4, 2024 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS Employ

June 12, 2024 EX-99.1

The Amended and Restated Definitive Healthcare Corp. 2023 Inducement Plan

Exhibit 99.1 DEFINITIVE HEALTHCARE CORP. AMENDED AND RESTATED 2023 INDUCEMENT PLAN 1. General. 1.1 Purpose. The purpose of the Definitive Healthcare Corp. 2023 Inducement Plan is to further align the interests of eligible participants with those of the Company’s stockholders by providing incentive compensation opportunities tied to the performance of the Company and its Common Stock. The Plan is i

June 12, 2024 S-8

As filed with the Securities and Exchange Commission on June 12, 2024

As filed with the Securities and Exchange Commission on June 12, 2024 Registration No.

June 12, 2024 EX-FILING FEES

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Definitive Healthcare Corp.

May 24, 2024 8-K

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS Employ

May 24, 2024 EX-10.2

Form of Executive Value Creation PSU Award Agreement under the Definitive Healthcare Corp. 2023 Inducement Plan (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-40815) filed with the SEC on May 24, 2024).

Exhibit 10.2 Definitive Healthcare Corp. 2023 Inducement Plan Restricted Stock Unit Award Agreement (Performance-Based) This Restricted Stock Unit Award Agreement (this “Agreement”) is made by and between Definitive Healthcare Corp., a Delaware corporation (the “Company”), and [] (the “Participant”), effective as of [], 20[] (the “Date of Grant”). RECITALS WHEREAS, the Company has adopted the Defi

May 24, 2024 EX-10.1

Employment Agreement, dated as of May 20, 2024, by and among Definitive Healthcare, LLC, Definitive Healthcare Corp. and Kevin Coop (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40815) filed with the SEC on May 24, 2024).

Exhibit 10.1 EMPLOYMENT AGREEMENT This Agreement (the “Agreement”), dated as of May 20, 2024, is made and entered into by and between, on the one hand, Definitive Healthcare, LLC, a Massachusetts limited liability company (the “Company”) and its parent company, Definitive Healthcare Corp., a Delaware corporation (“Parent”, and together with the Company, the “Company Group”), and, on the other hand

May 7, 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Definitive

May 7, 2024 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

May 7, 2024 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS Employe

May 7, 2024 EX-99.1

Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2024 First quarter revenue grew 7% year-over-year to $63.5 million

Exhibit 99.1 Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2024 First quarter revenue grew 7% year-over-year to $63.5 million Framingham, MA (May 7, 2024) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 20

April 9, 2024 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1

April 9, 2024 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

February 29, 2024 EX-FILING FEES

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Definitive Healthcare Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation  Rule Amount Registered (1)  Proposed Maximum  Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration  Fee Equity Class A Commo

February 29, 2024 S-8

As filed with the Securities and Exchange Commission on February 28, 2024

As filed with the Securities and Exchange Commission on February 28, 2024 Registration No.

February 28, 2024 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Definitive Heal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS E

February 28, 2024 EX-97.1

Definitive Healthcare Corp. Incentive Compensation Recoupment Policy.

Exhibit 97.1 Incentive Compensation Recoupment Policy 1. INTRODUCTION The Human Capital Management and Compensation Committee (the “HCM and Compensation Committee”) of the Board of Directors (the “Board”) of Definitive Healthcare Corp., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Re

February 28, 2024 EX-21.1

List of subsidiaries.

Exhibit 21.1 Subsidiaries of the Registrant Entity Name Jurisdiction of Incorporation AIDH TopCo, LLC Delaware AIDH Buyer, LLC Delaware Definitive Healthcare Holdings, LLC Delaware Definitive Healthcare, LLC Massachusetts Analytical Wizards, Inc Delaware Analytical Wizards Services Private Ltd India Monocl Holding Company, LLC Delaware Monocl Company, LLC Delaware Monocl AB Sweden Healthcare Sales

February 28, 2024 EX-99.1

Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2023 Fourth quarter revenue grew 9% year-over-year to $65.9 million Full year 2023 revenue grew 13% year-over-year to $251.4 million

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2023 Fourth quarter revenue grew 9% year-over-year to $65.9 million Full year 2023 revenue grew 13% year-over-year to $251.4 million Framingham, MA (February 28, 2024) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial

February 28, 2024 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40815 Definitive Heal

February 14, 2024 SC 13G/A

DH / Definitive Healthcare Corp. / ADVENT INTERNATIONAL CORP/MA - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Definitive Healthcare Corp. (Name of Issuer) CLASS A COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 24477E103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d

February 13, 2024 SC 13G/A

DH / Definitive Healthcare Corp. / Krantz Jason Ronald - SC 13G/A Passive Investment

SC 13G/A 1 jk-schedule13gaq124.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2)* Under the Securities Exchange Act of 1934 Definitive Healthcare Corp. (Name of Issuer) Class A common stock, $0.001 par value per share (Title of Class of Securities) 24477E103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of th

February 9, 2024 SC 13G/A

DH / Definitive Healthcare Corp. / SEA VII Management, LLC - SPECTRUM (SEA VII MANAGEMENT, LLC) - DEFINITIVE HEALTHCARE CORP -- SCH 13G/A(#2) Passive Investment

SC 13G/A 1 sptrm-sch13g18794.htm SPECTRUM (SEA VII MANAGEMENT, LLC) - DEFINITIVE HEALTHCARE CORP - SCH 13G/A(#2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Definitive Healthcare Corp. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 24477E103 (CUSIP

February 8, 2024 SC 13G/A

DH / Definitive Healthcare Corp. / Echo Street Capital Management LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

January 16, 2024 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024 DEFINITIVE HEALTHCARE CORP. (Exact name of registrant as specified in its charter) Delaware 001-40815 86-3988281 (State or other jurisdiction of incorporation) (Commi

January 16, 2024 EX-10.1

Separation Agreement and Release of Claims, dated as of January 12, 2024, by and between Definitive Healthcare Corp. and Robert Musslewhite (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40815) filed with the SEC on January 16, 2024).

Exhibit 10.1 DEFINITIVE HEALTHCARE, LLC January 12, 2024 Robert Musslewhite [***] [***] Re: Separation Agreement and Release of Claims Dear Robert: This letter sets forth the substance of the separation agreement (the “Agreement”) which Definitive Healthcare, LLC (the “Company”) and its parent company Definitive Healthcare Corp., a Delaware corporation (“Parent”) (together with the Company, the “C

January 16, 2024 EX-99.1

Definitive Healthcare Announces CEO Transition Jason Krantz, Founder and Executive Chairman, to Serve as Interim CEO Company Reaffirms Fourth Quarter 2023 Guidance and Issues Preliminary Guidance for 2024

Exhibit 99.1 Definitive Healthcare Announces CEO Transition Jason Krantz, Founder and Executive Chairman, to Serve as Interim CEO Company Reaffirms Fourth Quarter 2023 Guidance and Issues Preliminary Guidance for 2024 Framingham, MA, January 16, 2024 – Definitive Healthcare (Nasdaq: DH) (the “Company”), an industry leader in healthcare commercial intelligence, today announced that Robert Musslewhi

January 5, 2024 SC 13G

DH / Definitive Healthcare Corp. / Conestoga Capital Advisors, LLC - CONESTOGA CAPITAL ADVISORS Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Definitive Healthcare Corp (Name of Issuer) Class A Common Stock, par value $.001 (Title of Class of Securities) 24477E103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

January 4, 2024 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Definitive Health

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS Emp

January 4, 2024 EX-99.1

As we embark upon this new year, I’m writing to share some critical and difficult changes that we are making to our organization to best position us for the future.

Exhibit 99.1 Team, As we embark upon this new year, I’m writing to share some critical and difficult changes that we are making to our organization to best position us for the future. As we’ve discussed in Town Halls over the last several months, we embarked on “Go for GOLD” (“Grow, Optimize, Lead Definitive Healthcare”) to assess how we are currently performing and to develop a plan to transform

November 21, 2023 EX-10.1

Definitive Healthcare Corp. Severance Plan for Executives (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40815) filed with the SEC on November 21, 2023).

Exhibit 10.1 THE DEFINITIVE HEALTHCARE CORP. SEVERANCE PLAN FOR EXECUTIVES The Company has adopted the Plan, effective as of the Effective Date, to provide severance pay and benefits to eligible executives of the Company in connection with Qualifying Terminations on the terms and conditions provided for herein. All capitalized terms used herein are defined in Section 1. The Plan is sponsored by th

November 21, 2023 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS E

November 2, 2023 EX-10.4

Employment Agreement, dated October 2, 2023, between Carrie Lazorchak and Definitive Healthcare Corp.

Exhibit 10.4 EMPLOYMENT AGREEMENT This Agreement (the “Agreement”), dated as of October 2, 2023, is made and entered into by and between Definitive Healthcare, LLC, a Massachusetts limited liability company (the “Company”), and Carrie Lazorchak (the “Executive”). Introduction The Company desires to retain the services of the Executive pursuant to the terms and conditions set forth herein and the E

November 2, 2023 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS Em

November 2, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Defini

November 2, 2023 EX-99.1

Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2023 Third quarter revenue grew 14% year-over-year to $65.3 million

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2023 Third quarter revenue grew 14% year-over-year to $65.3 million Framingham, MA (November 2, 2023) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended Septem

October 5, 2023 EX-10.1

Separation Agreement, dated as of October 2, 2023, by and between Definitive Healthcare, LLC and Joseph Mirisola (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40815) filed with the SEC on October 5, 2023).

Exhibit 10.1 October 2, 2023 Joe Mirisola Re: Separation Agreement Dear Joe: This letter agreement (“Agreement”) sets forth the terms regarding the cessation of your employment with Definitive Healthcare, LLC (the “Company”). The effective date of cessation (i.e., your last day of employment) is the earlier of the Early Cessation Date (as defined below) or December 31, 2023 (with such effective da

October 5, 2023 EX-99.1

Definitive Healthcare Names Carrie Lazorchak as Chief Revenue Officer

Exhibit 99.1 Definitive Healthcare Names Carrie Lazorchak as Chief Revenue Officer Framingham, MA (October 5, 2023) – Definitive Healthcare Corp. (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that Carrie Lazorchak has been named Chief Revenue Officer, effective November 1, 2023. “I am thrilled to welcome Carrie Lazorchak to Definitive Healthcare as our new

October 5, 2023 8-K

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS Emp

September 8, 2023 EX-99.1

Definitive Healthcare Welcomes Scott Stephenson to Board of Directors

Exhibit 99.1 Definitive Healthcare Welcomes Scott Stephenson to Board of Directors Framingham, MA (September 8, 2023) – Definitive Healthcare Corp. (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced two changes to its Board of Directors. On September 6, 2023, Scott Stephenson, the former Chief Executive Officer of Verisk Analytics, joined the Board of Directors

September 8, 2023 8-K

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS E

September 6, 2023 EX-FILING FEES

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Definitive Healthcare Corp.

September 6, 2023 EX-99.3

Form of PSU Award Agreement under 2023 Inducement Plan (incorporated by reference to Exhibit 99.3 to the Company’s S-8 (File No. 333-274370) filed with the SEC on September 6, 2023).

Exhibit 99.3 Definitive Healthcare Corp. 2023 Inducement Plan Restricted Stock Unit Award Agreement (Performance-Based) This Restricted Stock Unit Award Agreement (this “Agreement”) is made by and between Definitive Healthcare Corp., a Delaware corporation (the “Company”), and (the “Participant”), effective as of , 20 (the “Date of Grant”). RECITALS WHEREAS, the Company has adopted the Definitive

September 6, 2023 EX-99.2

Form of RSU Award Agreement under 2023 Inducement Plan (incorporated by reference to Exhibit 99.2 to the Company’s S-8 (File No. 333-274370) filed with the SEC on September 6, 2023).

Exhibit 99.2 Definitive Healthcare Corp. 2023 Inducement Plan Restricted Stock Unit Award Agreement (Time-Based) This Restricted Stock Unit Award Agreement (this “Agreement”) is made by and between Definitive Healthcare Corp., a Delaware corporation (the “Company”), and (the “Participant”), effective as of , 20 (the “Date of Grant”). RECITALS WHEREAS, the Company has adopted the Definitive Healthc

September 6, 2023 EX-99.1

The Definitive Healthcare Corp. 2023 Inducement Plan (incorporated by reference to Exhibit 99.1 to the Company’s S-8 (File No. 333-274370) filed with the SEC on September 6, 2023).

Exhibit 99.1 THE DEFINITIVE HEALTHCARE CORP. 2023 INDUCEMENT PLAN 1. General. 1.1 Purpose. The purpose of the Definitive Healthcare Corp. 2023 Inducement Plan is to further align the interests of eligible participants with those of the Company’s stockholders by providing incentive compensation opportunities tied to the performance of the Company and its Common Stock. The Plan is intended to (a) pr

September 6, 2023 S-8

As filed with the Securities and Exchange Commission on September 6, 2023

As filed with the Securities and Exchange Commission on September 6, 2023 Registration No.

August 14, 2023 EX-99.1

Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2023 Second quarter revenue grew 12% year-over-year to $61.0 million

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2023 Second quarter revenue grew 12% year-over-year to $61.0 million Framingham, MA (August 14, 2023) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended June

August 14, 2023 EX-10.1

The Definitive Healthcare Corp. Director Compensation Plan.

Exhibit 10.1 DEFINITIVE HEALTHCARE CORP. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ADOPTED: APRIL 18, 2023 Each member of the Board of Directors (the “Board”) who is not (i) also serving as an employee of or consultant to Definitive Healthcare Corp. (the “Company”) or any of its subsidiaries or (ii) an employee of Advent International Corporation, or Spectrum Equity Management, L.P. or their respe

August 14, 2023 EX-99.2

Definitive Healthcare Acquires Populi Acquisition broadens Definitive Healthcare’s suite of healthcare commercial intelligence solutions with new data, analytics, and visualization tools tailor-built for the provider market

Exhibit 99.2 Definitive Healthcare Acquires Populi Acquisition broadens Definitive Healthcare’s suite of healthcare commercial intelligence solutions with new data, analytics, and visualization tools tailor-built for the provider market FRAMINGHAM, MA (August 14, 2023) – Definitive Healthcare (NASDAQ: DH), an industry leader in healthcare commercial intelligence, today announced its acquisition of

August 14, 2023 10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number

August 14, 2023 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-4

August 14, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Definitive Health

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS Emp

August 14, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Definitive

August 1, 2023 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS Emplo

August 1, 2023 EX-99.2

Email to Employees

Exhibit 99.2 Email to Employees Definitive Healthcare Team, I’m writing to share some very difficult news. Today, we’re reducing the size of our team by approximately 4% and saying goodbye to many talented friends and colleagues in the process. If you are among those impacted, you have already received an invitation to meet with your function leader and HR later this morning. As I’ve shared with y

August 1, 2023 NT 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Trans

NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the transitio

August 1, 2023 EX-99.1

Definitive Healthcare Reports Preliminary Financial Results for Second Quarter Fiscal Year 2023, Reaffirms Full Year Guidance for Revenue and Adjusted EBITDA, and Announces Restatement of Previously Issued Financials Q2 2023 Earnings Call Moved to Au

Exhibit 99.1 Definitive Healthcare Reports Preliminary Financial Results for Second Quarter Fiscal Year 2023, Reaffirms Full Year Guidance for Revenue and Adjusted EBITDA, and Announces Restatement of Previously Issued Financials Q2 2023 Earnings Call Moved to August 14, 2023 Framingham, MA (August 1, 2023) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an i

June 8, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Definitive Healthcar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS Employ

June 5, 2023 8-K

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS Employ

May 4, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Definitive Healthcare

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS Employe

May 4, 2023 EX-99

Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2023 First quarter revenue grew 18% year-over-year to $59.2 million

Exhibit 99.1 Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2023 First quarter revenue grew 18% year-over-year to $59.2 million Framingham, MA (May 4, 2023) – Definitive Healthcare Corp. (“Definitive Healthcare" or the "Company") (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2

May 4, 2023 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Definitive

May 3, 2023 CORRESP

May 3, 2023

CORRESP May 3, 2023 VIA EDGAR TRANSMISSION Jenifer Gallagher John Cannarella Division of Corporation Finance Office of Energy and Transportation Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.

April 20, 2023 DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

April 20, 2023 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

February 27, 2023 EX-10

Separation Agreement, dated as of November 1, 2022, by and among Definitive Healthcare, LLC and David Samuels.

Exhibit 10.26 November 1, 2022 David Samuels [XXXXXXX] [XXXXXXXX] Re: Separation Agreement Dear David: This letter agreement (“Agreement”) sets forth the terms regarding the cessation of your employment with Definitive Healthcare, LLC (the “Company”). The effective date of cessation (i.e., your last day of employment) is the earlier of the Early Cessation Date (as defined below) or December 31, 20

February 27, 2023 EX-FILING FEES

Filing Fee Table

EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Definitive Healthcare Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Cl

February 27, 2023 S-8

Power of Attorney (included on signature page to this Registration Statement).

S-8 As filed with the Securities and Exchange Commission on February 27, 2023 Registration No.

February 27, 2023 EX-10

Offer Letter to Kate Shamsuddin Jensen, dated February 3, 2015 (incorporated by reference to Exhibit 10.30 to the Company’s Annual Report on Form 10-K (File No. 001-40815) filed with the SEC on February 27, 2023).

EX-10 4 dh-ex1030.htm EX-10.30 Exhibit 10.30 February 3rd, 2015 Dear Kate: The following letter outlines an offer to join Definitive Healthcare in the capacity of Director of Product Strategy. I personally look forward to working with you to build our product, our brand and our client base in the healthcare community. Your compensation package will be comprised of the following: 1) Annual salary o

February 27, 2023 EX-10

Form of Executive Performance-Based Restricted Stock Unit Award Agreement under Definitive Healthcare Corp. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.17 to the Company’s Annual Report on Form 10-K (File No. 001-40815) filed with the SEC on February 27, 2023).

EX-10 2 dh-ex1017.htm EX-10.17 Exhibit 10.17 Definitive Healthcare Corp. 2021 Equity Incentive Plan Restricted Stock Unit Award Agreement (Performance-Based) This Restricted Stock Unit Award Agreement (this “Agreement”) is made by and between Definitive Healthcare Corp., a Delaware corporation (the “Company”), and [●] (the “Participant”), effective as of [●], 20[●] (the “Date of Grant”). RECITALS

February 27, 2023 EX-10

Definitive Healthcare Corp. Change in Control Severance Plan for Executives.

Exhibit 10.36 THE DEFINITIVE HEALTHCARE CORP. CHANGE IN CONTROL SEVERANCE PLAN FOR EXECUTIVES The Company has adopted the Plan, effective as of the Effective Date, to provide severance pay and benefits to eligible executives of the Company in connection with a Change in Control of the Company on the terms and conditions provided for herein. All capitalized terms used herein are defined in Section

February 27, 2023 10-K

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40815 Definitive Heal

February 23, 2023 EX-10

Amendment to Executive Chairman Agreement and Employment Agreement of Jason Krantz, dated as of February 16, 2023 (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-40815) filed with the SEC on February 23, 2023).

Exhibit 10.1 February 16, 2023 Jason Krantz RE: Amendment to Executive Chairman Agreement and Employment Agreement Dear Jason: You and Definitive Healthcare, LLC, a Massachusetts limited liability company (the “Company”) and its parent company Definitive Healthcare Corp., a Delaware corporation (“Parent”) (together with the Company, the “Company Group”) are parties to that certain Executive Chairm

February 23, 2023 EX-99

Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2022 Fourth quarter revenue grew 31% year-over-year to $60.6 million Full year 2022 revenue grew 34% to $222.7 million

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2022 Fourth quarter revenue grew 31% year-over-year to $60.6 million Full year 2022 revenue grew 34% to $222.7 million Framingham, MA (February 23, 2023) – Definitive Healthcare Corp. (“Definitive Healthcare" or the "Company") (Nasdaq: DH), an industry leader in healthcare commercial intelligence,

February 23, 2023 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 Definitive Heal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS E

February 23, 2023 EX-10

Definitive Healthcare Corp. Cash Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K (File No. 001-40815) filed with the SEC on February 23, 2023).

Exhibit 10.2 DEFINITIVE HEALTHCARE CORP. CASH INCENTIVE PLAN Effective February 16, 2023 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities, and (b) achieve the Company’s objectives. 2. Definitions. (a) “Actual Award” means, as to any Performance Period, the actual award (i

February 14, 2023 SC 13G

DH / Definitive Healthcare Corp - Class A / Echo Street Capital Management LLC Passive Investment

SC 13G 1 d994028513g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Definitive Healthcare Corp. (Name of Issuer) Class A Common Stock, $0.001 par value (Title of Class of Securities) 24477E103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria

February 14, 2023 SC 13G/A

DH / Definitive Healthcare Corp - Class A / SEA VII Management, LLC - SPECTRUM (SEA VII MANAGEMENT, LLC) - DEFINITIVE HEALTHCARE CORP -- SCH 13G/A(#1) Passive Investment

SC 13G/A 1 sptrm-sch13g18698.htm SPECTRUM (SEA VII MANAGEMENT, LLC) - DEFINITIVE HEALTHCARE CORP - SCH 13G/A(#1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Definitive Healthcare Corp. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 24477E103 (CUSIP

February 13, 2023 SC 13G/A

DH / Definitive Healthcare Corp - Class A / Krantz Jason Ronald - SC 13G/A Passive Investment

SC 13G/A 1 d371824dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 Definitive Healthcare Corp. (Name of Issuer) Class A common stock, $0.001 par value per share (Title of Class of Securities) 24477E103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this St

January 12, 2023 EX-99.1

Email to Employees

Exhibit 99.1 Email to Employees Definitive Healthcare team: Today I’m announcing the most difficult decision that we’ve ever had to make at Definitive Healthcare. We’re reducing the size of our team by around 6% and saying goodbye to many talented friends and colleagues in the process. If you are among those impacted, you have already received an invitation to meet with an ELT member later this mo

January 12, 2023 8-K

Regulation FD Disclosure, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2023 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS Em

November 3, 2022 EX-10.5

Amendment No. 1, dated October 31, 2022, to Credit Agreement, dated September 17, 2021, by and among Definitive Healthcare Holdings, LLC, AIDH Buyer, LLC, Bank of America, N.A. as Administrative Agent, the lenders party thereto and the issuing banks from time to time party thereto (incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q (File No.001-40815) filed with the SEC on November 3, 2022).

Exhibit 10.5 Execution Version AMENDMENT NO. 1 THIS AMENDMENT NO. 1 (this ?Amendment?), dated as of October 31, 2022, is entered into among Definitive Healthcare Holdings, LLC, a Delaware limited liability company (the ?Borrower?), AIDH Buyer, LLC, a Delaware limited liability company (?Holdings?), the other Loan Guarantors party hereto, the Lenders party thereto and BANK OF AMERICA, N.A., as admi

November 3, 2022 EX-99.2

Definitive Healthcare Names Jon Maack as President Effective November 3, 2022

Exhibit 99.2 Definitive Healthcare Names Jon Maack as President Effective November 3, 2022 FRAMINGHAM, MA ? November 3, 2022 ? Definitive Healthcare Corp. (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced Jon Maack has joined the company as President, effective November 3, 2022. Maack will report to Definitive Healthcare CEO Robert Musslewhite and have respons

November 3, 2022 EX-10.4

Amendment, dated August 9, 2022, to Restricted Stock Unit Award Agreements, issued under the Definitive Healthcare Corp. 2021 Equity Incentive Plan, between Robert Musslewhite and Definitive Healthcare Corp. (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40815) filed with the SEC on November 3, 2022).

Exhibit 10.4 Musslewhite 2021 RSU Amendment AMENDMENT TO RESTRICTED STOCK UNIT AWARD AGREEMENTS This Amendment (the ?Amendment?) to the Restricted Stock Unit Award Agreements (as defined below) between Robert Musslewhite (?Participant?) and Definitive Healthcare Corp. (the ?Company?) is effective as of August 9, 2022. RECITALS A. On October 7, 2021, the Company granted to Participant two restricte

November 3, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Defini

November 3, 2022 EX-99.1

Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2022 Third quarter revenue grew 33% year-over-year to $57.4 million

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2022 Third quarter revenue grew 33% year-over-year to $57.4 million Framingham, MA (November 3, 2022) ? Definitive Healthcare Corp. (?Definitive Healthcare" or the "Company") (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended Septem

November 3, 2022 8-K

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Definitive Healthcare Corp. (Exact name of Registrant as Specified in Its Charter) Commission File Number 1-40815 Delaware 86-3988281 (State of Incorporation) (IRS Em

November 3, 2022 EX-10.2

Form of Executive Restricted Stock Unit Award Agreement under Definitive Healthcare Corp. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-40815) filed with the SEC on November 3, 2022).

Exhibit 10.2 Definitive Healthcare Corp. 2021 Equity Incentive Plan Restricted Stock Unit Award Agreement This Restricted Stock Unit Award Agreement (this ?Agreement?) is made by and between Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and [?] (the ?Participant?), effective as of [?], 2022 (the ?Date of Grant?). RECITALS WHEREAS, the Company has adopted the Definitive Healt

November 3, 2022 EX-10.1

Employment Agreement, dated as of September 22, 2022, by and between Definitive Healthcare, LLC and Jonathan Maack (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40815) filed with the SEC on November 3, 2022).

Exhibit 10.1 EMPLOYMENT AGREEMENT This Agreement (the ?Agreement?), dated as of September 22, 2022, is made and entered into by and between Definitive Healthcare, LLC, a Massachusetts limited liability company (the ?Company?), and Jonathan Maack (the ?Executive?). Introduction The Company desires to retain the services of the Executive pursuant to the terms and conditions set forth herein and the

October 7, 2022 EX-4.4

Form of Indenture

Exhibit 4.4 DEFINITIVE HEALTHCARE CORP. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Sec

October 7, 2022 EX-4.7

Form of Preferred Stock Warrant Agreement and Warrant Certificate

Exhibit 4.7 DEFINITIVE HEALTHCARE CORP. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF , 20 DEFINITIVE HEALTHCARE CORP. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of , 20, between Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association

October 7, 2022 S-3ASR

As filed with the U.S. Securities and Exchange Commission on October 7, 2022

Table of Contents As filed with the U.S. Securities and Exchange Commission on October 7, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Delaware 86-3988281 (State or other jurisdiction of incorporati

October 7, 2022 EX-4.8

Form of Debt Securities Warrant Agreement and Warrant Certificate

Exhibit 4.8 DEFINITIVE HEALTHCARE CORP. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF , 20 DEFINITIVE HEALTHCARE CORP. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of , 20, between Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association

October 7, 2022 EX-FILING FEES

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Definitive Healthcare Corp.

October 7, 2022 EX-4.6

Form of Class A Common Stock Warrant Agreement and Warrant Certificate

Exhibit 4.6 DEFINITIVE HEALTHCARE CORP. AND , AS WARRANT AGENT FORM OF CLASS A COMMON STOCK WARRANT AGREEMENT DATED AS OF , 20 DEFINITIVE HEALTHCARE CORP. FORM OF CLASS A COMMON STOCK WARRANT AGREEMENT THIS CLASS A COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of , 20, between Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and [?], a [corporation] [national bank

October 3, 2022 EX-99.1

Definitive Healthcare Announces Changes to Board of Directors Sastry Chilukuri joins Board of Directors and Randy Winn departs

Exhibit 99.1 Definitive Healthcare Announces Changes to Board of Directors Sastry Chilukuri joins Board of Directors and Randy Winn departs FRAMINGHAM, MA ? October 3, 2022 ? Definitive Healthcare Corp. (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced two changes to its Board of Directors. On September 30, 2022, Sastry Chilukuri, who currently serves as co-ch

October 3, 2022 EX-10.1

Form of Director Restricted Stock Unit Award Agreement under Definitive Healthcare Corp. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40815) filed with the SEC on October 3, 2022).

EX-10.1 2 d383931dex101.htm EX-10.1 Exhibit 10.1 Definitive Healthcare Corp. 2021 Equity Incentive Plan Restricted Stock Unit Award Agreement Participant: [ ] Date of Grant: [ ] Vesting Start Date: [ ] RSUs Granted: [ ] This Restricted Stock Unit Award Agreement (this “Agreement”) is made by and between Definitive Healthcare Corp., a Delaware corporation (the “Company”), and Participant, effective

October 3, 2022 8-K

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 29, 2022 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Commission file number 1-40815 Delaware 86-3988281 (State of incorporation) (I.R.

August 4, 2022 EX-99.1

Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2022 Second quarter revenue grew 37% year-over-year to $54.5 million

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2022 Second quarter revenue grew 37% year-over-year to $54.5 million Framingham, MA (August 4, 2022) ? Definitive Healthcare Corp. (?Definitive Healthcare?) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended June 30, 2022. Second Q

August 4, 2022 EX-10.4

Restricted Stock Unit Award Agreement (83,333 time-based Restricted Stock Units), dated as of May 3, 2022, by and among Definitive Healthcare Corp. and Robert Musslewhite (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40815) filed with the SEC on August 4, 2022).

Definitive Healthcare Corp. 2021 Equity Incentive Plan Restricted Stock Unit Award Agreement This Restricted Stock Unit Award Agreement (this ?Agreement?) is made by and between Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and Robert Musslewhite (the ?Participant?), effective as of May 3, 2022 (the ?Date of Grant?). RECITALS WHEREAS, the Company has adopted the Definitive H

August 4, 2022 EX-10.5

Restricted Stock Unit Award Agreement (125,000 performance-based Restricted Stock Units), dated as of May 3, 2022, by and among Definitive Healthcare Corp. and Robert Musslewhite (incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40815) filed with the SEC on August 4, 2022)

Definitive Healthcare Corp. 2021 Equity Incentive Plan Restricted Stock Unit Award Agreement This Restricted Stock Unit Award Agreement (this ?Agreement?) is made by and between Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and Robert Musslewhite (the ?Participant?), effective as of May 3, 2022 (the ?Date of Grant?). RECITALS WHEREAS, the Company has adopted the Definitive H

August 4, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 4, 2022 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Commission file number 1-40815 Delaware 86-3988281 (State of incorporation) (I.R.S. E

August 4, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Definitive

August 4, 2022 EX-10.3

Restricted Stock Unit Award Agreement (333,322 time-based Restricted Stock Units), dated as of May 3, 2022, by and among Definitive Healthcare Corp. and Robert Musslewhite (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40815) filed with the SEC on August 4, 2022).

Definitive Healthcare Corp. 2021 Equity Incentive Plan Restricted Stock Unit Award Agreement This Restricted Stock Unit Award Agreement (this ?Agreement?) is made by and between Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and Robert Musslewhite (the ?Participant?), effective as of May 3, 2022 (the ?Date of Grant?). RECITALS WHEREAS, the Company has adopted the Definitive H

May 26, 2022 8-K

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 24, 2022 (Date of earliest event reported) DEFINITIVE HEALTHCARE CORP. (Exact name of registrant as specified in its charter) Delaware 1-40815 86-3988281 (State or other jurisdiction of incorporation) (Commission

May 5, 2022 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

May 5, 2022 EX-10.2

Executive Chairman Agreement, dated as of May 4, 2022, by and among Definitive Healthcare, LLC, Definitive Healthcare Corp. and Jason Krantz (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-40815) filed with the SEC on May 5, 2022).

Exhibit 10.2 Execution Version Executive Chairman Agreement THIS EXECUTIVE CHAIRMAN AGREEMENT (this “Agreement”), dated as of May 4, 2022, is entered into by and between, on the one hand Definitive Healthcare, LLC, a Massachusetts limited liability company (the “Company”) and its parent company Definitive Healthcare Corp., a Delaware corporation (“Parent”) (together with the Company, the “Company

May 5, 2022 EX-10.1

Amended and Restated Employment Agreement, dated as of May 4, 2022, by and among Definitive Healthcare, LLC, Definitive Healthcare Corp. and Robert Musslewhite (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40815) filed with the SEC on May 5, 2022).

Exhibit 10.1 Execution Version AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”), dated as of May 4, 2022 (the “Effective Date”), is made and entered into by and between, on the one hand, Definitive Healthcare, LLC, a Massachusetts limited liability company (the “Company”) and its parent company Definitive Healthcare Corp., a Delaware corpor

May 5, 2022 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Definitive

May 5, 2022 EX-99.1

Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2022 First quarter revenue grew 36% year-over-year to $50.1 million

Exhibit 99.1 Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2022 First quarter revenue grew 36% year-over-year to $50.1 million Framingham, MA (May 5, 2022) – Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March 31, 2022. First Quarte

May 5, 2022 8-K

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 3, 2022 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Commission file number 1-40815 Delaware 86-3988281 (State of incorporation) (I.R.S. Empl

May 5, 2022 EX-99.2

Definitive Healthcare Names Robert Musslewhite as CEO Effective August 1, 2022 Founder & CEO Jason Krantz will become Executive Chairman

Exhibit 99.2 Definitive Healthcare Names Robert Musslewhite as CEO Effective August 1, 2022 Founder & CEO Jason Krantz will become Executive Chairman FRAMINGHAM, MA – May 5, 2022 – Definitive Healthcare Corp. (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Board of Directors has appointed Robert Musslewhite as the company’s next CEO, effective Augus

April 12, 2022 DEF 14A

definitive proxy statement

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14

April 12, 2022 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

March 15, 2022 EX-10.12

2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to the Company's Annual Report on Form 10-K (File No. 001-40815) filed with the SEC on March 15, 2022.

Exhibit 10.12 THE DEFINITIVE HEALTHCARE CORP. 2021 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Definitive Healthcare Corp. 2021 Equity Incentive Plan is to further align the interests of eligible participants with those of the Company?s stockholders by providing incentive compensation opportunities tied to the performance of the Company and its Common Stock. The Plan is intended to advanc

March 15, 2022 EX-4.1

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Definitive Healthcare, a Delaware corporation, had one class of securities registered pursuant to Section 12 of the Securities and Exchange Act of 1934 (the ?Exchange Act?), as amended: Class A common stock, par value $0.001 per share (the ?Class A common stock?). The fol

March 15, 2022 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40815 Definitive Heal

February 23, 2022 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 18, 2022 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Commission file number 1-40815 Delaware 86-3988281 (State of incorporation) (I.R.S

February 23, 2022 EX-99.1

Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Year Fiscal 2021 Fourth quarter revenue grew 38% year-over-year to $46.3 million Full year 2021 revenue grew 40% to $166.2 million

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Year Fiscal 2021 Fourth quarter revenue grew 38% year-over-year to $46.3 million Full year 2021 revenue grew 40% to $166.2 million Framingham, MA (February 23, 2022) ? Definitive Healthcare Corp. (?Definitive Healthcare?) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced f

February 14, 2022 SC 13G

DH / Definitive Healthcare Corp - Class A / ADVENT INTERNATIONAL CORP/MA - SC 13G Passive Investment

SC 13G 1 brhc10033930sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Definitive Healthcare Corp. (Name of Issuer) CLASS A COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 24477E103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Stat

February 14, 2022 SC 13G

DH / Definitive Healthcare Corp - Class A / SEA VII Management, LLC - SPECTRUM (SEA VII MANAGEMENT, LLC) - DEFINITIVE HEALTHCARE CORP -- SCH 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ???)* Definitive Healthcare Corp. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 24477E103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to

February 14, 2022 EX-99.1

SCHEDULE 13G

EX-99.1 2 brhc10033930ex99-1.htm EXHIBIT 99.1 CUSIP No. 24477E103 SCHEDULE 13G Page 51 of 57 Pages EXHIBIT 99.1 JOINT FILING AGREEMENT Each of the undersigned, pursuant to Rule 13d-1(k)(1) under the Act, hereby agrees and acknowledges that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the Class A Com

February 11, 2022 SC 13G

DH / Definitive Healthcare Corp - Class A / Krantz Jason Ronald - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No.)* Under the Securities Exchange Act of 1934 Definitive Healthcare Corp. (Name of Issuer) Class A common stock, $0.001 par value per share (Title of Class of Securities) 24477E103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

November 19, 2021 424B4

11,000,000 Shares Definitive Healthcare Corp. Class A Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-261083 PROSPECTUS 11,000,000 Shares Definitive Healthcare Corp. Class A Common Stock We are offering 11,000,000 shares of Class A common stock of Definitive Healthcare Corp. Our Class A common stock is listed on Nasdaq Global Select Market (?Nasdaq?) under the symbol ?DH.? On November 17, 2021, the last sale price of our commo

November 16, 2021 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 10, 2021 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Commission file number 1-40815 Delaware 86-3988281 (State of incorporation) (I.R.S

November 15, 2021 EX-10.21

Stock and Unit Purchase Agreement, dated November 10, 2021, by and among Definitive Healthcare Corp. and the parties named therein (incorporated by reference to Exhibit 10.21 to the Company’s Registration Statement on Form S-1 (File No. 333-261083) filed with the SEC on November 15, 2021).

Exhibit 10.21 STOCK AND UNIT PURCHASE AGREEMENT THIS STOCK AND UNIT PURCHASE AGREEMENT (this ?Agreement?) is entered into as of November 10, 2021 by and among Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and certain persons listed on Schedule I hereto (each such securityholder a ?Seller? and collectively, the ?Sellers?). BACKGROUND A. The Company has determined to effect an

November 15, 2021 EX-1.1

Form of Underwriting Agreement.

Exhibit 1.1 Definitive Healthcare Corp. 11,000,000 Shares of Class A Common Stock Underwriting Agreement [?], 2021 Goldman Sachs & Co. LLC J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Barclays Capital Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o J.P. Morgan Securities LLC 383 Madison

November 15, 2021 CORRESP

DEFINITIVE HEALTHCARE CORP. 550 Cochituate Rd Framingham, MA 01701 November 15, 2021

DEFINITIVE HEALTHCARE CORP. 550 Cochituate Rd Framingham, MA 01701 November 15, 2021 VIA EDGAR AND EMAIL Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street, NE Washington, D.C. 20549-3561 Attn: Matthew Crispino Re: Definitive Healthcare Corp. Registration Statement on Form S-1 Filed on November 15, 2021 Ladies and Gentlemen: We refer to the registr

November 15, 2021 CORRESP

[Remainder of page intentionally left blank]

VIA EDGAR November 15, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Definitive Healthcare Corp. (the ?Company?) Registration Statement on Form S-1 (File No. 333-261083) Ladies and Gentlemen: As representatives of the several underwriters of the Company?s proposed public offering of its Class A common stock, we hereby join the Company?s request that the effe

November 15, 2021 S-1

As filed with the Securities and Exchange Commission on November 15, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Definitive Health

Table of Contents As filed with the Securities and Exchange Commission on November 15, 2021 Registration No.

November 8, 2021 EX-10.13

Nominating Agreement, dated September 17, 2021, between the Company and Jason Krantz (incorporated by reference to Exhibit 10.13 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40815) filed with the SEC on November 8, 2021).

Exhibit 10.13 NOMINATING AGREEMENT This Nominating Agreement (this ?Agreement?), dated as of September 17, 2021, by and among Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and Jason Krantz. WHEREAS, the Company has determined that it is in its best interests to effect an initial public offering (?IPO?) of shares of its Class A common stock, par value $0.001 per share (togeth

November 8, 2021 EX-3.3

Second Amended and Restated Limited Liability Company Agreement of AIDH TopCo, LLC (incorporated by reference to Exhibit 3.3 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40815) filed with the SEC on November 8, 2021).

Exhibit 3.3 SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT of AIDH TOPCO, LLC Dated as of September 14, 2021 WEIL:\98074461\9\40590.0003 Article 1 DEFINITIONS AND USAGE 5 Section 1.01. Definitions. 5 Section 1.02. Other Definitional and Interpretative Provisions 15 Article 2 THE COMPANY 16 Section 2.01. Formation 16 Section 2.02. Name 16 Section 2.03. Term 17 Section 2.04. Registe

November 8, 2021 EX-10.17

Independent Contractor Services Agreement dated as of October 1, 2021 by and between Definitive Healthcare Corp. and Kevin Shone as Contractor

Exhibit 10.17 INDEPENDENT CONTRACTOR SERVICES AGREEMENT THIS INDEPENDENT CONTRACTOR SERVICES AGREEMENT (the ?Agreement?) is made as of October 1, 2021 (the ?Effective Date?), by and between Definitive Healthcare LLC (?Company?), and Kevin P. Shone, AN INDIVIDUAL (?Contractor?). The parties hereby agree as follows: 1. Engagement of Contractor. Subject to the terms and conditions of this Agreement,

November 8, 2021 EX-10.8

Reorganization Agreement, dated September 14, 2021, between Definitive Healthcare Corp., AIDH TopCo, LLC and the parties named therein (incorporated by reference to Exhibit 10.8 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40815) filed with the SEC on November 8, 2021).

Exhibit 10.8 REORGANIZATION AGREEMENT This REORGANIZATION AGREEMENT (this ?Agreement?), dated as of September 14, 2021, is entered into by and among (a) AIDH TopCo, LLC, a Delaware limited liability company (the ?Company?); (b) Definitive Healthcare Corp., a Delaware corporation (?Pubco?) and (c) AIDH Holdings, Inc., a Delaware corporation (?Advent Blocker?); SE VII DHC AIV, L.P., a Delaware limit

November 8, 2021 EX-3.2

Amended and Restated Bylaws of Definitive Healthcare Corp. (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40815) filed with the SEC on November 8, 2021).

Weil Draft 9/13/2021 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF DEFINITIVE HEALTHCARE CORP. (a Delaware corporation) Effective September 14, 2021 ARTICLE I STOCKHOLDERS Section 1.01. Annual Meetings. The annual meeting of the stockholders of Definitive Healthcare Corp. (the ?Corporation?) for the election of directors and for the transaction of such other business as properly may come before such

November 8, 2021 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Defini

November 8, 2021 EX-10.14

Reimbursement Agreement, dated September 17, 2021, between Definitive Healthcare Corp. and Jason Krantz and certain other stockholders (incorporated by reference to Exhibit 10.14 to the Company’s Quarterly Report on Form10-Q (File No. 001-40815) filed with the SEC on November 8, 2021).

Exhibit 10.14 AIDH TOPCO, LLC CONFIDENTIAL September 17, 2021 AIDH TopCo, LLC 550 Cochituate Rd Framingham, MA 01701 Attention: David A. Samuels Expense Reimbursement Letter ? Transactions Ladies and Gentlemen: We are writing to acknowledge the agreement of certain parties listed on the signature pages hereto (?you? or ?your?) to work with AIDH TopCo, LLC (the ?Company?, ?our?, ?us?, or ?we?) and

November 8, 2021 EX-10.11

Nominating Agreement, dated September 17, 2021, between the Company and Advent (incorporated by reference to Exhibit 10.11 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40815) filed with the SEC on November 8, 2021).

Exhibit 10.11 NOMINATING AGREEMENT This Nominating Agreement (this ?Agreement?), dated as of September 17, 2021, by and among Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and Advent International GPE IX Limited Partnership (?Advent?). WHEREAS, the Company has determined that it is in its best interests to effect an initial public offering (?IPO?) of shares of its Class A co

November 8, 2021 EX-3.1

Amended and Restated Certificate of Incorporation of Definitive Healthcare Corp. (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40815) filed with the SEC on November 8, 2021).

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION of DEFINITIVE HEALTHCARE CORP. (Pursuant to Section 242 and 245 of the General Corporation Law of the State of Delaware) Definitive Healthcare Corp., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: FIRST: The name of the Corporation is Definitive Healthcare C

November 8, 2021 EX-10.16

Severance Agreement dated September 30, 2021 by and between Definitive Healthcare Corp. and Kevin Shone, effective September 30, 2021

Exhibit 10.16 September 30, 2021 BY EMAIL Kevin P. Shone 27 Grey Lane Lynnfield, MA 01940 [email protected] Dear Kevin: This letter agreement (the ?Agreement?) confirms our agreement relating to your separation from employment with Definitive Healthcare, LLC (the ?Company?). 1. Separation Date: Your employment with the Company shall end by your separation effective as of the close of busines

November 8, 2021 EX-99.1

Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2021 Third quarter revenue grew 43% year-over-year to $43.1 million

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2021 Third quarter revenue grew 43% year-over-year to $43.1 million Framingham, MA (November 8, 2021) ? Definitive Healthcare Corp. (?Definitive Healthcare?) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2021. Thi

November 8, 2021 EX-10.12

Nominating Agreement, dated September 17, 2021 between the Company and SE VII DHC AIV, L.P. (incorporated by reference to Exhibit 10.12 to the Company’s Quarterly Report on Form10-Q (File No. 001-40815) filed with the SEC on November 8, 2021).

Exhibit 10.12 NOMINATING AGREEMENT This Nominating Agreement (this ?Agreement?), dated as of September 17, 2021, by and among Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and SE VII DHC AIV, L.P. (?Spectrum?). WHEREAS, the Company has determined that it is in its best interests to effect an initial public offering (?IPO?) of shares of its Class A common stock, par value $0.

November 8, 2021 EX-10.10

Tax Receivable Agreement, dated September 14, 2021, between Definitive Healthcare Corp. and the TRA Parties (incorporated by reference to Exhibit 10.10 to the Company’s Quarterly Report on Form10-Q (File No. 001-40815) filed with the SEC on November 8, 2021).

Exhibit 10.10 TAX RECEIVABLE AGREEMENT by and among DEFINITIVE HEALTHCARE CORP. AIDH TOPCO, LLC the several TRA HOLDERS (as defined herein) and OTHER TRA HOLDERS FROM TIME TO TIME PARTY HERETO Dated as of September 14, 2021 CONTENTS Page Article I. DEFINITIONS 2 Section 1.1 Definitions 2 Section 1.2 Rules of Construction 13 Article II. DETERMINATION OF REALIZED TAX BENEFIT 14 Section 2.1 Basis Adj

November 8, 2021 8-K

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 8, 2021 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Commission file number 1-40815 Delaware 86-3988281 (State of incorporation) (I.R.S.

November 8, 2021 EX-10.9

Registration Rights Agreement, dated September 14, 2021, by and among Definitive Healthcare Corp. and the Continuing Pre-IPO LLC Members (incorporated by reference to Exhibit 10.9 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40815) filed with the SEC on November 8, 2021).

Exhibit 10.9 REGISTRATION RIGHTS AGREEMENT by and among Definitive Healthcare Corp. and the other parties hereto September 14, 2021 TABLE OF CONTENTS Section 1. Certain Definitions 3 Section 2. Registration Rights 7 2.1. Demand Registrations 7 2.2. Piggyback Registrations 11 2.3. Holdback Agreements 13 2.4. Registration Procedures 13 2.5. Registration Expenses 18 2.6. No Required Sale 19 2.7. Inde

November 5, 2021 DRS

Confidential Treatment Requested by Definitive Healthcare Corp. Pursuant to 17 C.F.R. Section 200.83 As submitted confidentially with the Securities and Exchange Commission on November 5, 2021 This draft registration statement has not been publicly f

Table of Contents Confidential Treatment Requested by Definitive Healthcare Corp. Pursuant to 17 C.F.R. Section 200.83 As submitted confidentially with the Securities and Exchange Commission on November 5, 2021 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNI

October 8, 2021 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 7, 2021 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Commission file number 1-40815 Delaware 86-3988281 (State of incorporation) (I.R.S.

October 8, 2021 EX-99.1

Robert Musslewhite Joins Definitive Healthcare as President

Exhibit 99.1 Robert Musslewhite Joins Definitive Healthcare as President FRAMINGHAM, MA ? (October 7, 2021) ? Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that Robert Musslewhite has joined the company as President, a newly created role on the company?s Executive Leadership Team. ?Robert?s combination of deep healthcare expertise and

October 8, 2021 EX-10.1

Employment Agreement dated October 7, 2021 by and between Definitive Healthcare Corp. and Robert Musslewhite (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40815) filed with the SEC on October 7, 2021).

Exhibit 10.1 EMPLOYMENT AGREEMENT This Agreement (the ?Agreement?), dated as of October 7, 2021 (?Effective Date?), is made and entered into by and between Definitive Healthcare, LLC, a Massachusetts limited liability company (the ?Company?), and Robert Musslewhite (the ?Executive?). Introduction The Company desires to retain the services of the Executive pursuant to the terms and conditions set f

October 1, 2021 EX-99.1

Definitive Healthcare Appoints Kathleen A. Winters to Board of Directors

EX-99.1 2 d217445dex991.htm EX-99.1 EXHIBIT 99.1 Definitive Healthcare Appoints Kathleen A. Winters to Board of Directors FRAMINGHAM, MA (October 1, 2021) – Definitive Healthcare (NASDAQ: DH), an industry leader in healthcare commercial intelligence, today announced the appointment of Kathleen A. Winters to its Board of Directors and its Audit Committee. “Kathleen’s wealth of financial and operati

October 1, 2021 8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 1, 2021 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Commission file number 1-40815 Delaware 86-3988281 (State of incorporation) (I.R.S.

September 20, 2021 8-K

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 17, 2021 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Commission file number 1-40815 Delaware 86-3988281 (State of incorporation) (I.R.

September 20, 2021 EX-10.1

Credit Agreement, dated September 17, 2021, by and among DH Holdings and Administrative Agent, the lenders party thereto and the issuing banks from time to time party thereto (incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K (File No. 001-40815), filed with the SEC on September 20, 2021).

Exhibit 10.1 Published Deal CUSIP Number 24477GAA6 Published Revolver CUSIP Number: 24477GAB4 Published Term Loan A CUSIP Number: 24477GAC2 CREDIT AGREEMENT dated as of September 17, 2021 among DEFINITIVE HEALTHCARE HOLDINGS, LLC, as the Borrower, AIDH BUYER, LLC, as Holdings, THE FINANCIAL INSTITUTIONS PARTY HERETO as Lenders and Issuing Banks, and BANK OF AMERICA, N.A., as Administrative Agent,

September 20, 2021 EX-99.1

Definitive Healthcare Announces Closing of Public Offering

EX-99.1 3 d402153dex991.htm EX-99.1 EXHIBIT 99.1 Definitive Healthcare Announces Closing of Public Offering FRAMINGHAM, MA— (September 20, 2021) – Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the closing of its previously announced initial public offering of 17,888,888 shares of its Class A common stoc

September 16, 2021 424B4

15,555,555 Shares Definitive Healthcare Corp. Class A Common Stock

424B4 1 d127783d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-258990 PROSPECTUS 15,555,555 Shares Definitive Healthcare Corp. Class A Common Stock This is an initial public offering of Class A common stock by Definitive Healthcare Corp. In this prospectus, unless the context otherwise requires, “Definitive,” the “Company,” “we,” “us” and “our” refer (i) pr

September 15, 2021 8-A12B

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Definitive Healthcare Corp. (Exact Name of Registrant as Specified in Its Charter) Delaware 86-3988281 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification

September 15, 2021 S-8

As filed with the Securities and Exchange Commission on September 14, 2021

As filed with the Securities and Exchange Commission on September 14, 2021 Registration No.

September 13, 2021 S-1/A

As filed with the Securities and Exchange Commission on September 13, 2021

S-1/A Table of Contents As filed with the Securities and Exchange Commission on September 13, 2021 Registration No.

September 10, 2021 CORRESP

DEFINITIVE HEALTHCARE CORP. 550 Cochituate Rd Framingham, MA 01701 September 10, 2021

DEFINITIVE HEALTHCARE CORP. 550 Cochituate Rd Framingham, MA 01701 September 10, 2021 VIA EDGAR AND EMAIL Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street, NE Washington, D.C. 20549-3561 Attn: Matthew Crispino Re: Definitive Healthcare Corp. Registration Statement on Form S-1 (File No. 333-258990) Ladies and Gentlemen: We refer to the registratio

September 10, 2021 CORRESP

[Remainder of page intentionally left blank]

VIA EDGAR September 10, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Definitive Healthcare Corp. (the ?Company?) Registration Statement on Form S-1 (File No. 333-258990) Ladies and Gentlemen: As representatives of the several underwriters of the Company?s proposed initial public offering of its Class A common stock, we hereby join the Company?s request that

September 7, 2021 EX-10.19

Stock and Unit Purchase Agreement, dated September 7, 2021, by and among Definitive Health Care Corp. and the parties named therein (incorporated by reference to Exhibit 10.19 to Amendment No. 2 to the Company’s Registration Statement on Form S-1 (File No. 333-258990) filed with the SEC on September 7, 2021).

Exhibit 10.19 STOCK AND UNIT PURCHASE AGREEMENT THIS STOCK AND UNIT PURCHASE AGREEMENT (this ?Agreement?) is entered into as of September 7, 2021 by and among Definitive Healthcare Corp., a Delaware corporation (the ?Company?) and certain persons listed on Schedule I hereto (each such securityholder a ?Seller? and collectively, the ?Sellers?). BACKGROUND A. The Board of Directors of the Company (t

September 7, 2021 EX-10.18

Form of Reimbursement Agreement between Definitive Healthcare Corp. and Jason Krantz and certain other stockholders.

Exhibit 10.18 DEFINTIIVE HEALTHCARE CORP. CONFIDENTIAL September , 2021 Definitive Healthcare Corp. 550 Cochituate Rd Framingham, MA 01701 Attention: David A. Samuels Expense Reimbursement Letter – Transactions Ladies and Gentlemen: We are writing to acknowledge the agreement of certain parties listed on the signature pages hereto (“you” or “your”) to work with Definitive Healthcare Corp. (the “Co

September 7, 2021 S-1/A

As filed with the Securities and Exchange Commission on September 7, 2021

Table of Contents As filed with the Securities and Exchange Commission on September 7, 2021 Registration No.

September 7, 2021 EX-1.1

Form of Underwriting Agreement.

EX-1.1 2 d127783dex11.htm EX-1.1 Exhibit 1.1 Definitive Healthcare Corp. [•] Shares of Common Stock Underwriting Agreement [•], 2021 Goldman Sachs & Co. LLC J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Barclays Capital Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o J.P. Morgan Securitie

September 7, 2021 CORRESP

767 Fifth Avenue

767 Fifth Avenue New York, NY 10153-0119 +1 212 310 8000 tel +1 212 310 8007 fax September 7, 2021 VIA EDGAR TRANSMISSION Matthew Crispino Staff Attorney Division of Corporation Finance Office of Technology Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.

August 27, 2021 EX-4.1

Form of Certificate of Class A Common Stock.

Exhibit 4.1 DEFINITIVE HEALTHCARE CORP. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SEE REVERSE SIDE FOR CERTAIN DEFINITIONS CUSIP 24477E 10 3 THIS CERTIFIES THAT is the owner of BY FULLY PAID AND NON-ASSESSABLE CLASS A COMMON SHARES, $0.001 PAR VALUE, OF (Brooklyn, AMERICAN COUNTERSIGNED DEFINITIVE HEALTHCARE CORP. New STOCKAND transferable on the books of the Corporation by the holder h

August 27, 2021 S-1/A

As filed with the Securities and Exchange Commission on August 27, 2021

S-1/A Table of Contents As filed with the Securities and Exchange Commission on August 27, 2021 Registration No.

August 20, 2021 EX-10.9

Employment Agreement, dated January 29, 2021, by and between Definitive Healthcare, LLC and Richard Booth (incorporated by reference to Exhibit 10.9 to the Company’s Registration Statement on Form S-1 (File No. 333-258990) filed with the SEC on August 20, 2021).

Exhibit 10.9 EMPLOYMENT AGREEMENT This Agreement (the ?Agreement?), dated as of January 29th, 2021 (?Effective Date?), is made and entered into by and between Definitive Healthcare, LLC, a Massachusetts limited liability company (the ?Company?), and Richard Booth (the ?Executive?). Introduction The Company desires to retain the services of the Executive pursuant to the terms and conditions set for

August 20, 2021 EX-10.17

Form of Nominating Agreement between the Company and Jason Krantz

Exhibit 10.17 NOMINATING AGREEMENT This Nominating Agreement (this ?Agreement?), dated as of , 2021, by and among Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and Jason Krantz. WHEREAS, the Company has determined that it is in its best interests to effect an initial public offering (?IPO?) of shares of its Class A common stock, par value $0.001 per share (together with the

August 20, 2021 EX-10.2

2021 Equity Incentive Plan

Exhibit 10.2 THE DEFINITIVE HEALTHCARE CORP. 2021 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Definitive Healthcare Corp. 2021 Equity Incentive Plan is to further align the interests of eligible participants with those of the Company?s stockholders by providing incentive compensation opportunities tied to the performance of the Company and its Common Stock. The Plan is intended to advance

August 20, 2021 EX-10.7

2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.7 to the Company’s Registration Statement on Form S-1 (File No. 333-258990) filed with the SEC on August 20, 2021).

Exhibit 10.7 THE DEFINITIVE HEALTHCARE CORP. 2021 EMPLOYEE STOCK PURCHASE PLAN 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees and/or Eligible Service Providers of either the Company or a Designated Company may be given an opportunity to purchase Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees and/or Eligible Serv

August 20, 2021 EX-10.8

Employment Agreement, dated February 18, 2015, by and between Definitive Healthcare, LLC and Jason Krantz (incorporated by reference to Exhibit 10.8 to the Company’s Registration Statement on Form S-1 (File No. 333-258990) filed with the SEC on August 20, 2021).

Exhibit 10.8 EMPLOYMENT AGREEMENT This Agreement (the ?Agreement?), dated as of February 18, 2015, is made and entered into by and between Definitive Healthcare, LLC, a Massachusetts limited liability company (the ?Company?), and Jason Krantz (the ?Executive?). Introduction Reference is made to the Securities Purchase Agreement, dated on or about the date hereof, by and among the Definitive Health

August 20, 2021 EX-10.11

Credit Agreement, dated July 16, 2019, by and among DH Holdings, AIDH Buyer, LLC, Administrative Agent, the lenders party thereto and the issuing banks from time to time party thereto.

Exhibit 10.11 CREDIT AGREEMENT Dated as of July 16, 2019 among AIDH FINANCE SUB, LLC, and following the consummation of the Merger, DEFINITIVE HEALTHCARE HOLDINGS, LLC as the Borrower, AIDH BUYER, LLC, as Holdings, THE FINANCIAL INSTITUTIONS PARTY HERETO as Lenders and Issuing Banks, and OWL ROCK CAPITAL CORPORATION, as Administrative Agent and an Issuing Bank OWL ROCK CAPITAL ADVISORS LLC, as Lea

August 20, 2021 EX-10.12

Form of Reorganization Agreement between Definitive Healthcare Corp., AIDH TopCo, LLC and the parties named therein

EX-10.12 18 d127783dex1012.htm EX-10.12 Exhibit 10.12 REORGANIZATION AGREEMENT This REORGANIZATION AGREEMENT (this “Agreement”), dated as of , 2021, is entered into by and among (a) AIDH TopCo, LLC, a Delaware limited liability company (the “Company”); (b) Definitive Healthcare Corp., a Delaware corporation (“Pubco”) and (c) AIDH Holdings, Inc., a Delaware corporation (“Advent Blocker”); SE VII DH

August 20, 2021 EX-10.5

Form of 2021 Executive Officer and Director Indemnification Agreement for Definitive Healthcare Corp. (incorporated by reference to Exhibit 10.6 to the Company’s registration statement (File No. 333-258990) filed with the SEC on August 20, 2021)

Exhibit 10.5 Definitive Healthcare Corp. 2021 Equity Incentive Plan Restricted Stock Unit Award Agreement This Restricted Stock Unit Award Agreement (this ?Agreement?) is made by and between Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and (the ?Participant?), effective as of , 2021 (the ?Date of Grant?). RECITALS WHEREAS, the Company has adopted the Definitive Healthcare C

August 20, 2021 EX-10.10

Employment Agreement, dated February 1, 2021, by and between Definitive Healthcare, LLC and David Samuels (incorporated by reference to Exhibit 10.10 to the Company’s Registration Statement on Form S-1 (File No. 333-258990) filed with the SEC on August 20, 2021).

Exhibit 10.10 EMPLOYMENT AGREEMENT This Agreement (the ?Agreement?), dated as of February 1, 2021 (?Effective Date?), is made and entered into by and between Definitive Healthcare, LLC, a Massachusetts limited liability company (the ?Company?), and David Samuels (the ?Executive?). Introduction The Company desires to retain the services of the Executive pursuant to the terms and conditions set fort

August 20, 2021 EX-21.1

List of subsidiaries (incorporated by reference to Exhibit 21.1 to the Company's Registration Statement on Form S-1 (File No. 333-258990) filed with the SEC on August 20, 2021).

EX-21.1 24 d127783dex211.htm EX-21.1 Exhibit 21.1 Subsidiaries of the Registrant Entity Name Jurisdiction of Incorporation AIDH TopCo, LLC Delaware AIDH Buyer, LLC Delaware Definitive Healthcare Holdings, LLC Delaware Definitive Healthcare, LLC Massachusetts Healthcare Sales Enablement, Inc. Delaware Monocl Holding Company Delaware Monocl Company Delaware Monocl AB Sweden

August 20, 2021 S-1

Form S-1

S-1 Table of Contents As filed with the Securities and Exchange Commission on August 20, 2021 Registration No.

August 20, 2021 EX-3.1

Form of Amended and Restated Certificate of Incorporation of Definitive Healthcare Corp. to be in effect prior to the consummation of the offering made under this Registration Statement.

EX-3.1 2 d127783dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION of DEFINITIVE HEALTHCARE CORP. (Pursuant to Section 242 and 245 of the General Corporation Law of the State of Delaware) Definitive Healthcare Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: FIRST: The name of the Corpo

August 20, 2021 EX-10.1

2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333-258990) filed with the SEC on August 20, 2021).

Exhibit 10.1 AIDH TOPCO, LLC 2019 EQUITY INCENTIVE PLAN ARTICLE I ESTABLISHMENT, DEFINITIONS AND PURPOSE 1.1 Establishment. AIDH Topco, LLC, a Delaware limited liability company (the ?Company?), hereby establishes the AIDH Topco, LLC 2019 Equity Incentive Plan (the ?Plan?). The Plan shall become effective as of September 13, 2019. 1.2 Definitions. Capitalized terms used but not otherwise defined h

August 20, 2021 EX-3.2

Form of Amended and Restated Bylaws of Definitive Healthcare Corp. to be in effect prior to the consummation of the offering made under this Registration Statement.

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF DEFINITIVE HEALTHCARE CORP. (a Delaware corporation) Effective , 2021 ARTICLE I STOCKHOLDERS Section 1.01. Annual Meetings. The annual meeting of the stockholders of Definitive Healthcare Corp. (the ?Corporation?) for the election of directors and for the transaction of such other business as properly may come before such meeting shall be held at such pla

August 20, 2021 CORRESP

767 Fifth Avenue

767 Fifth Avenue New York, NY 10153-0119 +1 212 310 8000 tel +1 212 310 8007 fax August 20, 2021 VIA EDGAR TRANSMISSION Matthew Crispino Staff Attorney Division of Corporation Finance Office of Technology Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.

August 20, 2021 EX-10.6

Form of 2021 Executive Officer and Director Indemnification Agreement for Definitive Healthcare Corp. (incorporated by reference to Exhibit 10.6 to the Company’s Registration Statement on Form S-1 (File No. 333-258990) filed with the SEC on August 20, 2021).

Exhibit 10.6 FORM OF DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into as of , 2021, between Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and (?Indemnitee?). Capitalized terms not defined elsewhere in this Agreement are used as defined in Section 13. WHEREAS, the Board of Directors of the Company (the ?B

August 20, 2021 EX-10.15

Form of Nominating Agreement between the Company and Advent.

Exhibit 10.15 NOMINATING AGREEMENT This Nominating Agreement (this ?Agreement?), dated as of , 2021, by and among Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and (?Advent?). WHEREAS, the Company has determined that it is in its best interests to effect an initial public offering (?IPO?) of shares of its Class A common stock, par value $0.001 per share (together with the Co

August 20, 2021 EX-10.14

Form of Tax Receivable Agreement between Definitive Healthcare Corp. and the TRA Parties.

Exhibit 10.14 TAX RECEIVABLE AGREEMENT by and among DEFINITIVE HEALTHCARE CORP. AIDH TOPCO, LLC the several TRA HOLDERS (as defined herein) and OTHER TRA HOLDERS FROM TIME TO TIME PARTY HERETO Dated as of [Month] [ ], 2021 CONTENTS Page Article I. DEFINITIONS 2 Section 1.1 Definitions 2 Section 1.2 Rules of Construction. Unless otherwise specified herein: 13 Article II. DETERMINATION OF REALIZED T

August 20, 2021 EX-3.3

Form of Second Amended and Restated Limited Liability Company Agreement of AIDH TopCo, LLC, to be in effect prior to the consummation of the offering made under this Registration Statement.

Exhibit 3.3 SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT of AIDH TOPCO, LLC Dated as of , 2021 ARTICLE 1 DEFINITIONS AND USAGE 1 Section 1.01. Definitions 1 Section 1.02. Other Definitional and Interpretative Provisions 11 ARTICLE 2 THE COMPANY 12 Section 2.01. Formation 12 Section 2.02. Name 12 Section 2.03. Term 12 Section 2.04. Registered Agent and Registered Office 12 Sectio

August 20, 2021 EX-3.5

Bylaws of Definitive Healthcare Corp., as currently in effect.

Exhibit 3.5 BYLAWS OF DEFINITIVE HEALTHCARE CORP. A DELAWARE CORPORATION PREAMBLE These Bylaws are subject to, and governed by, the General Corporation Law of the State of Delaware (the ?Delaware General Corporation Law?) and the Certificate of Incorporation (the ?Certificate?) of Definitive Healthcare Corp., a Delaware corporation (the ?Corporation?). In the event of a direct conflict between the

August 20, 2021 EX-10.4

Form of executive equity award agreements under 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company’s Registration Statement on Form S-1 (File No. 333-258990) filed with the SEC on August 20, 2021).

Exhibit 10.4 Definitive Healthcare Corp. 2021 Equity Incentive Plan Restricted Stock Unit Award Agreement This Restricted Stock Unit Award Agreement (this ?Agreement?) is made by and between Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and (the ?Participant?), effective as of , 2021 (the ?Date of Grant?). RECITALS WHEREAS, the Company has adopted the Definitive Healthcare C

August 20, 2021 EX-10.13

Form of Registration Rights Agreement by and among Definitive Healthcare Corp. and the Continuing Pre-IPO LLC Members.

Exhibit 10.13 REGISTRATION RIGHTS AGREEMENT by and among Definitive Healthcare Corp. and the other parties hereto , 2021 TABLE OF CONTENTS Section 1. Certain Definitions 1 Section 2. Registration Rights 5 2.1. Demand Registrations 5 2.2. Piggyback Registrations 9 2.3. Holdback Agreements 11 2.4. Registration Procedures 11 2.5. Registration Expenses 16 2.6. No Required Sale 16 2.7. Indemnification

August 20, 2021 EX-10.3

Form of equity award agreements under 2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company’s Registration Statement on Form S-1 (File No. 333-258990) filed with the SEC on August 20, 2021).

Exhibit 10.3 AIDH TOPCO, LLC 2019 EQUITY INCENTIVE PLAN TOPCO CLASS B UNIT GRANT AGREEMENT THIS CLASS B UNIT GRANT AGREEMENT (the ?Agreement?) is made as of September 18, 2019 (the ?Grant Date?) among AIDH Topco, LLC, a Delaware limited liability company (the ?Company?), AIDH Management Holdings, LLC a Delaware limited liability company (the ?Participant?), and (the ?Service Provider?). R E C I T

August 20, 2021 EX-3.4

Certificate of Incorporation of Definitive Healthcare Corp., as currently in effect.

Exhibit 3.4 CERTIFICATE OF INCORPORATION OF DEFINITIVE HEALTHCARE CORP. THE UNDERSIGNED, being a natural person for the purpose of organizing a corporation under the General Corporation Law of the State of Delaware, hereby certifies that: FIRST: The name of the Corporation is Definitive Healthcare Corp. (the ?Corporation?). SECOND: The address of its registered office in the State of Delaware is 1

August 20, 2021 EX-10.16

Form of Nominating Agreement between the Company and SE VII DHC AIV, L.P.

Exhibit 10.16 NOMINATING AGREEMENT This Nominating Agreement (this ?Agreement?), dated as of , 2021, by and among Definitive Healthcare Corp., a Delaware corporation (the ?Company?), and SE VII DHC AIV, L.P. (?Spectrum?). WHEREAS, the Company has determined that it is in its best interests to effect an initial public offering (?IPO?) of shares of its Class A common stock, par value $0.001 per shar

August 5, 2021 EX-3.3

CERTIFICATE OF INCORPORATION DEFINITIVE HEALTHCARE CORP.

EX-3.3 2 filename2.htm Exhibit 3.3 CERTIFICATE OF INCORPORATION OF DEFINITIVE HEALTHCARE CORP. THE UNDERSIGNED, being a natural person for the purpose of organizing a corporation under the General Corporation Law of the State of Delaware, hereby certifies that: FIRST: The name of the Corporation is Definitive Healthcare Corp. (the “Corporation”). SECOND: The address of its registered office in the

August 5, 2021 EX-21.1

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Entity Name Jurisdiction of Incorporation AIDH TopCo, LLC Delaware AIDH Buyer, LLC Delaware Definitive Healthcare Holdings, LLC Delaware Definitive Healthcare, LLC Massachusetts Healthcare Sales Enablement, Inc. Delaware Monocl Holding Company Delaware Monocl Company Delaware Monocl AB Sweden

August 5, 2021 EX-3.4

BYLAWS OF DEFINITIVE HEALTHCARE CORP. A DELAWARE CORPORATION

Exhibit 3.4 BYLAWS OF DEFINITIVE HEALTHCARE CORP. A DELAWARE CORPORATION PREAMBLE These Bylaws are subject to, and governed by, the General Corporation Law of the State of Delaware (the ?Delaware General Corporation Law?) and the Certificate of Incorporation (the ?Certificate?) of Definitive Healthcare Corp., a Delaware corporation (the ?Corporation?). In the event of a direct conflict between the

August 5, 2021 DRSLTR

767 Fifth Avenue

767 Fifth Avenue New York, NY 10153-0119 +1 212 310 8000 tel +1 212 310 8007 fax August 5, 2021 VIA EDGAR TRANSMISSION Matthew Crispino Staff Attorney Division of Corporation Finance Office of Technology Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.

August 5, 2021 EX-10.9

CREDIT AGREEMENT Dated as of July 16, 2019 AIDH FINANCE SUB, LLC, and following the consummation of the Merger, DEFINITIVE HEALTHCARE HOLDINGS, LLC as the Borrower, AIDH BUYER, LLC, as Holdings, THE FINANCIAL INSTITUTIONS PARTY HERETO as Lenders and

EX-10.9 4 filename4.htm Exhibit 10.9 CREDIT AGREEMENT Dated as of July 16, 2019 among AIDH FINANCE SUB, LLC, and following the consummation of the Merger, DEFINITIVE HEALTHCARE HOLDINGS, LLC as the Borrower, AIDH BUYER, LLC, as Holdings, THE FINANCIAL INSTITUTIONS PARTY HERETO as Lenders and Issuing Banks, and OWL ROCK CAPITAL CORPORATION, as Administrative Agent and an Issuing Bank OWL ROCK CAPIT

August 5, 2021 DRS/A

Amendment No. 2 to confidential submission As submitted confidentially with the Securities and Exchange Commission on August 5, 2021 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all inf

Table of Contents Amendment No. 2 to confidential submission As submitted confidentially with the Securities and Exchange Commission on August 5, 2021 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

June 30, 2021 DRSLTR

767 Fifth Avenue

767 Fifth Avenue New York, NY 10153-0119 +1 212 310 8000 tel +1 212 310 8007 fax June 30, 2021 VIA EDGAR TRANSMISSION Matthew Crispino Staff Attorney Division of Corporation Finance Office of Technology Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.

June 30, 2021 EX-10.6

EMPLOYMENT AGREEMENT

EX-10.6 2 filename2.htm Exhibit 10.6 EMPLOYMENT AGREEMENT This Agreement (the “Agreement”), dated as of February 18, 2015, is made and entered into by and between Definitive Healthcare, LLC, a Massachusetts limited liability company (the “Company”), and Jason Krantz (the “Executive”). Introduction Reference is made to the Securities Purchase Agreement, dated on or about the date hereof, by and amo

June 30, 2021 EX-10.7

EMPLOYMENT AGREEMENT

EX-10.7 3 filename3.htm Exhibit 10.7 EMPLOYMENT AGREEMENT This Agreement (the “Agreement”), dated as of January 29th, 2021 (“Effective Date”), is made and entered into by and between Definitive Healthcare, LLC, a Massachusetts limited liability company (the “Company”), and Richard Booth (the “Executive”). Introduction The Company desires to retain the services of the Executive pursuant to the term

June 30, 2021 DRS/A

Amendment No. 1 to confidential submission As submitted confidentially with the Securities and Exchange Commission on June 30, 2021 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all info

DRS/A 1 filename1.htm Table of Contents Amendment No. 1 to confidential submission As submitted confidentially with the Securities and Exchange Commission on June 30, 2021 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMM

June 30, 2021 EX-10.8

EMPLOYMENT AGREEMENT

EX-10.8 4 filename4.htm Exhibit 10.8 EMPLOYMENT AGREEMENT This Agreement (the “Agreement”), dated as of February 1, 2021 (“Effective Date”), is made and entered into by and between Definitive Healthcare, LLC, a Massachusetts limited liability company (the “Company”), and David Samuels (the “Executive”). Introduction The Company desires to retain the services of the Executive pursuant to the terms

May 28, 2021 DRSLTR

767 Fifth Avenue

767 Fifth Avenue New York, NY 10153-0119 +1 212 310 8000 tel +1 212 310 8007 fax May 28, 2021 Alexander D.

May 28, 2021 DRS

As submitted confidentially with the Securities and Exchange Commission on May 28, 2021 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential

Table of Contents As submitted confidentially with the Securities and Exchange Commission on May 28, 2021 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential.

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista